-transparent.png){kind=logo}
We have studied the pharmacokinetics of phenprocoumon with and without co-administration of frusemide and probenecid in two groups of 17 healthy volunteers. Frusemide 40 mg b.i.d. for 7 days did not interact with phenprocoumon to a significant extent. Probenecid 500 mg q.i.d. for 7 days significantly accelerated the overall elimination of phenprocoumon, as indicated by a decrease in AUC from 295 to 157 micrograms.h.ml-1, and a reduction in the fraction of the dose excreted by the kidneys. The data are consistent with inhibition of the glucuronidation of phenprocoumon by probenecid. Its accelerated elimination may be a consequence of the increased formation of hydroxylated metabolites.
H Mönig, and
M Böhm, and
E E Ohnhaus, and
W Kirch
May 1993,
Antimicrobial agents and chemotherapy,
H Mönig, and
M Böhm, and
E E Ohnhaus, and
W Kirch
April 1994,
International journal of clinical pharmacology and therapeutics,
H Mönig, and
M Böhm, and
E E Ohnhaus, and
W Kirch
January 1999,
European journal of clinical pharmacology,
H Mönig, and
M Böhm, and
E E Ohnhaus, and
W Kirch
April 1969,
Thrombosis et diathesis haemorrhagica,
H Mönig, and
M Böhm, and
E E Ohnhaus, and
W Kirch
January 1986,
American journal of veterinary research,
H Mönig, and
M Böhm, and
E E Ohnhaus, and
W Kirch
May 1982,
Antimicrobial agents and chemotherapy,
H Mönig, and
M Böhm, and
E E Ohnhaus, and
W Kirch
August 1994,
Clinical pharmacology and therapeutics,
H Mönig, and
M Böhm, and
E E Ohnhaus, and
W Kirch
August 2021,
The Journal of infection,
H Mönig, and
M Böhm, and
E E Ohnhaus, and
W Kirch
June 1995,
British journal of clinical pharmacology,
H Mönig, and
M Böhm, and
E E Ohnhaus, and
W Kirch
March 1972,
Acta medica Scandinavica,
